From: Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Tumor type | Phase/participants | Immune checkpoint inhibitors classification | Combination intervention | Status | ClinicalTrials.gov identifier |
---|---|---|---|---|---|
Unresectable, recurrent, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma | 3/371 | PD-L1 inhibitors | Avelumab + BSC VS physician’s choice + BSC | Active, not recruiting | NCT02625623 |
Various advanced cancers | 3/939 | PD-1 and CTLA-4 inhibitors | Nivolumab + ipilimumab or nivolumab + fluorouracil + cisplatin VS fluorouracil + cisplatin | Recruiting | NCT03143153 |
Esophageal neoplasms | 3/700 | PD-1 inhibitors | Pembrolizumab + cisplatin and 5-fluorouracil (5-FU) VS placebo + cisplatin and 5-FU | Recruiting | NCT03189719 |
Esophageal carcinoma| esophagogastric junction carcinoma | 3/720 | PD-1 inhibitors | Pembrolizumab (MK-3475) VS Investigator’s Choice Standard Therapy | Active, not recruiting | NCT02564263 |
Gastric cancer | 3/700 | PD-1 inhibitors | Nivolumab + S-1 therapy or CapeOX therapy VS placebo+ S-1 therapy or CapeOX therapy | Recruiting | NCT03006705 |
Gastric cancer | 2,3/680 | PD-1 inhibitors | ONO-4538 + chemotherapy | Active, not recruiting | NCT02746796 |
Gastric cancer| gastroesophageal junction cancer | 3/1649 | PD-1 and CTLA-4 inhibitors | Nivolumab + ipilimumab or nivolumab + chemotherapy VS chemotherapy alone | Recruiting | NCT02872116 |
Gastric cancer| Gastroesophageal junction cancer | 3/860 | PD-1 inhibitors | Pembrolizumab (MK-3475) + chemotherapy VS placebo + chemotherapy | Recruiting | NCT03221426 |
Stomach neoplasms | 3/780 | PD-1 inhibitors | Pembrolizumab (MK-3475) + chemotherapy VS placebo + chemotherapy | Not yet recruiting | NCT03675737 |
Gastric neoplasms| gastroesophageal junction adenocarcinoma | 3/732 | PD-1 inhibitors | Pembrolizumab/Placebo + trastuzumab + Chemotherapy | Recruiting | NCT03615326 |
Gastric adenocarcinoma | 3/764 | PD-1 inhibitors | Pembrolizumab as monotherapy, or pembrolizumab + Cisplatin + 5-fluorouracil (5-FU) or capecitabine; placebo + cisplatin + 5-FU or capecitabine | Active, not recruiting | NCT02494583 |
Biliary tract neoplasms | 3/390 | PD-1 inhibitors | KN035 + gemcitabine + oxaliplatin VS gemcitabine + oxaliplatin | Recruiting | NCT03478488 |
Hepatocellular carcinoma | 3/330 | PD-1 inhibitors | Pembrolizumab (MK-3475) or placebo + Best supportive care | Recruiting | NCT03062358 |
Hepatocellular Carcinoma | 3/480 | PD-L1 inhibitors | Atezolizumab + bevacizumab VS sorafenib | Recruiting | NCT03434379 |
Hepatocellular carcinoma | 3/1200 | PD-L1 and CTLA-4 inhibitors | Durvalumab + tremelimumab | Recruiting | NCT03298451 |
Pancreatic cancer stage IV | 2/40 | PD-1 inhibitors | Nivolumab + cabiralizumab + gemcitabine VS gemcitabine | Not yet recruiting | NCT03697564 |
Colorectal cancer | 3/363 | PD-L1 inhibitors | Cobimetinib + atezolizumab and atezolizumab monotherapy VS regorafenib | Active, not recruiting | NCT02788279 |
Colorectal adenocarcinoma| mismatch repair deficiency | 3/347 | PD-L1 inhibitors | Atezolizumab, bevacizumab, Mfolfox6 VS bevacizumab, Mfolfox6 VS atezolizumab | Recruiting | NCT02997228 |
Colon Adenocarcinoma| DNA repair disorder | 3/700 | PD-L1 and CTLA-4 inhibitors | Combination chemotherapy with or without atezolizumab | Recruiting | NCT02912559 |
Colorectal cancer | 3/180 | PD-1 inhibitors | Nivolumab with standard of care therapy VS standard of care therapy for first-line treatment | Recruiting | NCT03414983 |